Hansa Biopharma AB (HNSBF)
3.65
0.00 (0.00%)
USD |
OTCM |
Nov 13, 16:00
Hansa Biopharma Revenue (Quarterly): 4.689M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 4.689M |
| June 30, 2024 | 3.219M |
| March 31, 2024 | 5.398M |
| December 31, 2023 | 4.748M |
| September 30, 2023 | 2.117M |
| June 30, 2023 | 3.488M |
| March 31, 2023 | 2.321M |
| December 31, 2022 | 2.880M |
| September 30, 2022 | 6.398M |
| June 30, 2022 | 2.698M |
| March 31, 2022 | 3.250M |
| December 31, 2021 | 1.744M |
| September 30, 2021 | 0.5727M |
| June 30, 2021 | 0.5395M |
| March 31, 2021 | 1.075M |
| December 31, 2020 | 0.4452M |
| September 30, 2020 | 0.0861M |
| June 30, 2020 | 0.0644M |
| March 31, 2020 | 0.092M |
| December 31, 2019 | 0.1253M |
| September 30, 2019 | 0.068M |
| June 30, 2019 | 0.0627M |
| Date | Value |
|---|---|
| March 31, 2019 | 0.1001M |
| December 31, 2018 | 0.1532M |
| September 30, 2018 | 0.0541M |
| June 30, 2018 | 0.104M |
| March 31, 2018 | 0.0726M |
| December 31, 2017 | 0.1217M |
| September 30, 2017 | 0.0834M |
| June 30, 2017 | 0.0787M |
| March 31, 2017 | 0.1186M |
| December 31, 2016 | 0.0601M |
| September 30, 2016 | 0.1065M |
| June 30, 2016 | 0.066M |
| March 31, 2016 | 0.0695M |
| December 31, 2015 | 0.2082M |
| September 30, 2015 | 0.0623M |
| June 30, 2015 | 0.0628M |
| March 31, 2015 | 0.4626M |
| December 31, 2014 | 0.0211M |
| September 30, 2014 | |
| June 30, 2014 | 0.0529M |
| March 31, 2014 | 0.2495M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.0644M
Minimum
Jun 2020
6.398M
Maximum
Sep 2022
2.298M
Average
2.219M
Median
Revenue (Quarterly) Benchmarks
| Abliva AB | -- |
| Oncopeptides AB | 0.26M |
| BioInvent International AB | 1.23M |
| BioArctic AB | 4.673M |
| Camurus AB | 46.21M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -10.00M |
| Total Expenses (Quarterly) | 15.96M |
| EPS Diluted (Quarterly) | -0.1475 |
| Enterprise Value | 278.10M |
| Gross Profit Margin (Quarterly) | 76.62% |
| Profit Margin (Quarterly) | -213.3% |
| Earnings Yield | -29.56% |
| Normalized Earnings Yield | -29.56 |